These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29719240)

  • 1. Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer.
    Guney Eskiler G; Cecener G; Dikmen G; Egeli U; Tunca B
    Eur J Pharm Sci; 2018 Jul; 120():73-88. PubMed ID: 29719240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
    Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
    Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
    Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
    Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
    Yang S; Lee JY; Hur H; Oh JH; Kim MH
    BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity.
    How CW; Rasedee A; Manickam S; Rosli R
    Colloids Surf B Biointerfaces; 2013 Dec; 112():393-9. PubMed ID: 24036474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
    Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
    Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
    Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
    Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers.
    Beh CY; How CW; Foo JB; Foong JN; Selvarajah GT; Rasedee A
    Drug Des Devel Ther; 2017; 11():771-782. PubMed ID: 28352153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro model for the development of acquired tamoxifen resistance.
    Guney Eskiler G; Cecener G; Tunca B; Egeli U
    Cell Biol Toxicol; 2016 Dec; 32(6):563-581. PubMed ID: 27585693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity.
    Fontana G; Maniscalco L; Schillaci D; Cavallaro G; Giammona G
    Drug Deliv; 2005; 12(6):385-92. PubMed ID: 16253954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
    Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
    Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
    Han X; Li Q; Liu C; Wang C; Li Y
    J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
    Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
    Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
    Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
    Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
    Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
    Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
    Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
    Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell.
    Lee S; Lee H; Jeong D; Ham J; Park S; Choi EH; Kim SJ
    Free Radic Biol Med; 2017 Sep; 110():280-290. PubMed ID: 28666851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.